ImmunoVaccine Technologies, Inc. (IVT)
Biotech Specialty Pharma
1819 Granville St. Suite 303
Halifax, Nova Scotia B3J 3R1 Canada
phone: (902) 492-1819
fax: (902) 492-0888
Symbol private
Exchange
Founded 0
Employees
www.immunovaccine.com
Research Sector Biotech Specialty Pharma
Summary Description
Innovative vaccine vehicles that provide improved, long-lasting immunity
Management
Randal Chase, CEO; Ron Smith, VP of Finance
Ownership
Financials


* numbers in thousands

 
Keywords
vaccine, liposome, antigen, immunization, immune response
http://www.immunovaccine.com/images/banner.gif

Comment | Printable Version | Nov. 19, 2008
If you work for ImmunoVaccine Technologies, Inc. (IVT) and want to update this profile, click here

Description
ImmunoVaccine Technologies, Inc. (IVT) develops breakthrough vaccine vehicles that provide long-lasting immunity with a single administration, without boosting or significant side effects.
Products / Services
The VacciMax Platform uses an improved immunizing delivery system of antigens, which are molecules that serve to stimulate the immune response. The result is an improved vaccine product that provides significant, long lasting immunity.
Technology / Differentiation
The VacciMax Platform uses a liposome based antigen vaccine formulation in conjunction with VacciMax technology to produce superior vaccine products. The VacciMax technology serves to stabilize the antigenic liposomes, which historically have only contributed marginally to the production of an immune response. VacciMax's liposome stabilization results in higher-grade vaccines that produce unparalleled immune responses, even from previously considered "poor" antigens.
Market / Customers
During 2003 to 2006 the U.S. vaccine market has grown at a projected growth rate of 9.3%, and is anticipated to maintain the same rate throughout 2008. IVT addresses vaccine production in both infectious and non-infectious diseases.
Status
In January 2008, IVT announced that it would receive $3 million from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). This funding will enable IVT to undertake a $6 million project to develop new potent immune enhancement systems. IVT also announced that it was meeting with Health Canada's regulatory affairs division, the Biologics and Genetic Therapies Directorate, to discuss requirements for a Phase I clinical trial application. On June 5, 2008, IVT, Inc. announced it has entered into a collaborative research agreement with Bioject to assess utilization of the Biojector® 2000 for the delivery of IVT's patented vaccine enhancement platform, DepoVaxTM.


2008-11-22-159